Caris Life Sciences is an Irving, Texas-based leading TechBio company actively developing and commercializing solutions to transform healthcare through comprehensive molecular profiling (Whole Genome, Whole Exome, and Whole Transcriptome Sequencing), advanced AI and machine learning, the MI Profile molecular profiling service, the Caris Assure liquid biopsy service, the Caris Detect multi-cancer early detection blood test, and the broader Caris molecular profiling platform, and the company is in the middle of a fiscal second quarter that demonstrates the kind of molecular-profiling pivot the TechBio cohort has been waiting for. Q2 2026 total revenue of $263.7 million was 45 percent above the prior-year quarter's $181.4 million, the molecular profiling services revenue of $252.3 million was 55 percent above the prior-year quarter's $162.9 million, and the company completed approximately 59,200 clinical cases (an increase of approximately 18 percent year over year). The combination of the 45 percent total revenue growth, the 55 percent molecular profiling services revenue growth, the 18 percent clinical case volume growth, the 500 basis points of gross margin expansion from 63 percent to 68 percent, the $0.6 million net loss (a clean swing from the prior-year quarter's $71.8 million net loss), the $55.7 million of positive Adjusted EBITDA, the $28.5 million of positive net cash from operating activities, and the raised 2026 revenue guidance to $1.03 to $1.04 billion representing 27 to 28 percent growth is the cleanest single-sentence read on what the TechBio business model is producing, and the combination is the source of the operating-leverage spread the equity offers the buy-side.
The numbers tell the story with the kind of operational detail the TechBio equity has been waiting for. The Q2 2026 total revenue of $263.7 million was driven primarily by the 55 percent growth in molecular profiling services revenue, with the increase driven by the increase in total clinical case volume and ASP improvements. The Q2 2026 molecular profiling services revenue of $252.3 million was 55 percent above the prior-year quarter's $162.9 million. The Q2 2026 clinical case volume of approximately 59,200 included approximately 48,300 MI Profile cases and approximately 10,700 Caris Assure cases, with the clinical case volume more than 12 percent above the prior quarter. The Q2 2026 clinical cases included more than 114,000 whole exome-whole transcriptome tests with over 345,000 total oncology tests.
The Q2 2026 gross profit of $179.6 million was 58.0 percent above the prior-year quarter's $113.7 million, and the Q2 2026 gross margin of 68 percent was approximately 500 basis points above the prior-year quarter's 63 percent. The 500 basis points of gross margin expansion is the cleanest single read on the operating-leverage spread the company is producing, and the gross margin expansion is the source of the operating-leverage spread the company is producing.
The Q2 2026 operating expenses of $152.7 million were 16 percent above the prior-year quarter's $131.7 million, with the operating expense growth primarily driven by headcount-related costs. The operating expense growth of 16 percent was below the total revenue growth of 45 percent, producing the operating-leverage spread.
The Q2 2026 net loss of $0.6 million was a clean swing from the prior-year quarter's net loss of $71.8 million, and the Q2 2026 net loss per share of $0.00 was a clean swing from the prior-year quarter's net loss per share of $7.97. The Q2 2026 Adjusted EBITDA of $55.7 million was a clean improvement from the prior-year quarter.
The Q2 2026 net cash provided by operating activities of $28.5 million was a 291 percent improvement from the prior-year quarter's $7.3 million, with the improvement driven by the improved total clinical case volume and the ASP improvements. The Q2 2026 free cash flow of $6.4 million is the cleanest single read on the cash-generation profile the company is producing.
The 2026 revenue guidance has been raised to $1.03 billion to $1.04 billion, representing growth of 27 to 28 percent compared to 2025, and the company has reaffirmed its guidance to clinical therapy selection volume growth of approximately 20 percent compared to 2025. The raised 2026 revenue guidance is the cleanest single read on the management confidence in the operating profile the company is producing.
The question the next four quarters resolve is whether the company can sustain the 45 percent revenue growth and the 500 basis points of gross margin expansion through the second half of fiscal 2026, and whether the raised 2026 revenue guidance of $1.03 to $1.04 billion is achievable. A Q3 2026 print that continues the 40 to 45 percent revenue growth and the gross margin expansion would confirm the operating profile is sustainable. A Q3 2026 print that shows revenue growth decelerating or the gross margin compressing would force the market to reprice the equity for a more modest terminal value.